cefepime   Click here for help

GtoPdb Ligand ID: 10772

Synonyms: BMY-28142 | BMY28142 | CFPM | Maxipime® | Renapime®
Approved drug
cefepime is an approved drug (FDA (1996), UK (2017))
Compound class: Synthetic organic
Comment: Cefepime is a semisynthetic, broad-spectrum, fourth-generation cephalosporin antibacterial [1-2]. It was removed from the World Health Organization's List of Essential Medicines in 2019.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 203.58
Molecular weight 480.12
XLogP -3.06
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CO/N=C(/c1csc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)[O-])C[N+]1(C)CCCC1
Isomeric SMILES CO/N=C(/c1csc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)[O-])C[N+]1(C)CCCC1
InChI InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Cefepime is reserved for the treatment of severe nosocomial pneumonia, particularly infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa. It does not have a Europe-wide EMA authorisation but is approved by most of the individual nations. Cefepime + taniborbactam (formerly VNRX-5133, an injectable beta-lactamase inhibitor with in vitro activity against both serine- and metallo-beta-lactamases) is proposed as an option for infections due to carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa, and to combat engineerable bioterror pathogens such as Burkholderia species.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03840148 Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections Phase 3 Interventional VenatoRx Pharmaceuticals, Inc. A study examining the combination of the 4th gen cephalosporin cefepime and the broad-spectrum β-lactamse inhibitor taniborbactam.
External links Click here for help